If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksprobiotix health Regulatory News (PBX.PL)

Share Price Information for probiotix health (PBX.PL)

Share Price is delayed by 15 minutes
Get Live Data
7.75    0.00 (0.00%)
Bid:
7.50
Ask:
8.00
Spread: 0.50 (6.667%)
Market Cap: £12.26m
PBX.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday probiotix health Share Chart

New Commercial Partnership in Greece

16 Sep 2024 07:00

RNS Number : 1743E
Probiotix Health PLC
16 September 2024
 

 

16 September 2024

 

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

 

New Commercial Partnership in Greece

 

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a commercial partnership with Greece based consumer brands specialist Eifron SA ("Eifron").

 

As part of the terms of the agreement, Eifron will introduce YourBiotixBP tablets, containing LPLDL®, under its existing probiotic consumer brand, with the anticipated product launch expected to be in Q1 2025. Through this strategic partnership, Eifron will expand its own portfolio by including a product for cholesterol and blood pressure lowering based on LPLDL®. The addition of other products from the ProBiotix portfolio will be evaluated by the parties on an ongoing basis.

 

ProBiotix Health has received a purchase order from Eifron, with the first sales planned for Greece and thereafter in selected regions in Europe.

 

Founded in 2011, Eifron specialises in innovative healthcare solutions and holds a strong market position, particularly in Greece where it is among the top five brands in the country. Its core focus is addressing unmet medical needs by developing and distributing advanced product solutions for the health sector, with particularly close ties among pharmacies and healthcare professionals. The current Eifron product portfolio includes pharmaceuticals, supplements, and medical devices.

 

Steen Andersen, CEO of ProBiotix, commented: "This exceptional opportunity to work with a science driven market leader like Eifron represents another significant milestone in our efforts to expand our reach and broaden the availability of our innovative cardiometabolic health product solutions in Europe.

 

"Eifron's reputation and expertise in the health sector and their commitment to natural solutions makes them an ideal partner for us."

 

Elias Kartasiadis, CEO of Eifron, added: "We are thrilled to partner with ProBiotix Health and bring their scientifically-backed products to our markets. This partnership aligns perfectly with our mission to provide our customers with effective and natural health solutions.

 

"We believe this collaboration will help us expand our reach and offer differentiation and added value to the growing group of consumers looking to improve their cardiometabolic health."

For further information, please contact:

 

ProBiotix Health plc

https://probiotixhealth-ir.com/

Steen Andersen, Chief Executive

Contact via Walbrook below

Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) Mark Anwyl

Tel: 020 7220 9793

 

 

Walbrook PR Ltd

Anna Dunphy

probiotix@walbrookpr.com Mob: 07876 741 001

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXBBGDCRDBDGSX
12
Date   Source Headline
23rd Jun 20261:00 pmRNSResult of AGM
1st Jun 20267:00 amRNSNew Partnership Agreement in Slovakia
29th May 20267:00 amRNSNotice of AGM
26th May 20267:00 amRNSNew Strategic Alliance in Spain and Portugal
30th Mar 20267:00 amRNSFinal Results and Investor Presentation
16th Mar 20267:00 amRNSNotice of Results and Investor Presentation
16th Mar 20267:00 amRNSNotice of Results and Investor Presentation
17th Feb 20267:00 amRNSPDMR Shareholding
16th Feb 202612:30 pmRNSStatement re Share Price Movement
5th Feb 20265:00 pmRNSHolding(s) in Company
4th Feb 20267:00 amRNSDirector/PDMR Shareholding
21st Jan 20267:00 amRNSTrading Update
3rd Nov 20257:00 amRNSMove from Access to Apex Segment of Aquis
23rd Oct 20257:00 amRNSAppointment of Aquis Corporate Adviser
20th Oct 20257:00 amRNSNew Commercial Partnership in Australia
14th Oct 20252:00 pmRNSDirector/PDMR Shareholding
14th Oct 20257:00 amRNSNew Commercial Partnership in Sweden
13th Oct 20257:00 amRNSQ3 2025 Trading Update and Grant of Options
8th Sep 20257:00 amRNSUnaudited Interim Results to 30 June 2025
15th Jul 20257:00 amRNSTrading Update and Notice of Results
27th Jun 202512:35 pmRNSResult of AGM and Notice of Trading Update
9th Jun 20254:15 pmRNSPDMR Shareholding
5th Jun 20255:30 pmRNSNotice of Annual General Meeting - Clarification
30th May 20257:01 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSNotice of AGM
29th May 20257:00 amRNSFinal Results
7th May 20257:00 amRNSNotice of Results and Investor Presentation
28th Mar 20257:00 amRNSNew Partnership Agreement in South Korea
20th Feb 20257:01 amRNSGrant of Options
20th Feb 20257:01 amRNSGrant of Options
20th Feb 20257:00 amRNSMajor new Supply Agreement in the Far East
20th Feb 20257:00 amRNSMajor new Supply Agreement in the Far East
23rd Jan 20257:00 amRNSTrading Update
5th Nov 20243:33 pmRNSDirector/PDMR Shareholding
1st Nov 202410:56 amRNSResult of Requisitioned General Meeting
30th Oct 20247:00 amRNSRequisition update
18th Oct 20247:00 amRNSResponse to Publication of Circular by ProBiotix
15th Oct 20247:00 amRNSPublication of Circular and Notice of GM
10th Oct 20247:00 amRNSNew Commercial Partnership in Mexico
8th Oct 20247:00 amRNSQ3 2024 Trading Update
7th Oct 20247:00 amRNSAppointment of Non-Executive Director
3rd Oct 20247:00 amRNSNew Commercial Partnership in Ukraine
30th Sep 20242:03 pmRNSTotal Voting Rights
27th Sep 202411:23 amRNSHolding(s) in Company
25th Sep 20247:05 amRNSResponse to General Meeting Requisition
25th Sep 20247:00 amRNSGeneral Meeting Requisition Notice
16th Sep 20247:00 amRNSNew Commercial Partnership in Greece
6th Sep 20242:08 pmRNSResponse to OptiBiotix Health plc announcement
4th Sep 20247:00 amRNSShare Subscription and Proposed Board Appointment
30th Aug 20247:00 amRNSHalf-year Report
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.